Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening

Yan Wang, Wai Kit Law, Jian Shu Hu, Huang Quan Lin, Tsz Ming Ip, David Chi Cheong Wan

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

(Chemical Equation Presented) We first identified fluorescein, ketazolam, antrafenine, darifenacin, fosaprepitant, paliperidone, risperidone, pimozide, trovafloxacin, and levofloxacin as inhibitors of fatty acid binding protein 4 using molecular docking screening from FDA-approved drugs. Subsequently, the biochemical characterizations showed that levofloxacin directly inhibited FABP4 activity in both the in vitro ligand displacement assay and cell-based function assay. Furthermore, levo floxacin did not induce adipogenesis in adipocytes, which is the major adverse effect of FABP4 inhibitors.

Original languageEnglish (US)
Pages (from-to)3046-3050
Number of pages5
JournalJournal of Chemical Information and Modeling
Volume54
Issue number11
DOIs
StatePublished - Nov 24 2014

Fingerprint Dive into the research topics of 'Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening'. Together they form a unique fingerprint.

Cite this